Home / News

2026-02-27: Keythera’s KF-0210 Phase 2a Study Accepted for Podium Presentat...

Suzhou, China, February 27, 2026 — Keythera (Suzhou) Biopharmaceuticals Co., Ltd. (“Keythera”) today announced that the abstract of its exploratory ...

2025-12-15

Keythera Pharma | KF-0210 Delivers Rapid, Deep, and Durable Symptom Relief in Phase IIa Knee Osteoarthritis Study

Suzhou — Keythera Pharma today announced positive results from a Phase IIa exploratory study of KF-0210, the first oral EP4 antagonist to enter human clinical trials for osteoarthritis (OA) and chronic pain....

More >>

2025-10-14

EP4 Antagonist KF-0210 Phase II Clinical Trial for Osteoarthritis Treatment Launched

The Phase II clinical trial of KF0210, an EP4 antagonist independently developed by Keythera Pharmaceuticals, for the treatment of knee osteoarthritis has officially commenced. On October 12, 2025, the first participant has successfully received the initial dose....

More >>

2024-03-01

Keythera Pharmaceuticals' Innovative Drug KBP-2205 Tablets Receive NMPA Approval for Clinical Trials

On March 1, 2024, Keythera (Suzhou) Bio-Pharmaceuticals Co., Limited (Keythera Pharmaceuticals) announced that its independently discovered innovative drug

More >>

2023-04-29

Keythera was honored with the "Top 15 Best Newcomer Award" on the 2022 China Healthcare Industry Investment and Financing Glory List

Recently, the prestigious list of the "2022 China Healthcare Industry Investment and Financing Glory List" was announced by CHC Healthcare Consulting in collaboration with CITIC Securities. ...

More >>

2023-04-04

Keythera Biopharmaceuticals Will Present the Research Findings on KF-0210 at AACR 2023

Keythera Biopharmaceuticals is a small molecule innovation company focused on the fields of oncology and autoimmune diseases.

More >>

2023-02-07

KF-0210 Tablets was Approved for Phase II Clinical Trial for Osteoarthritis

Recently, Keythera (Suzhou) Biopharmaceuticals Co., Ltd. (“Keythera”) has received approval from the National Medical Products Administration (NMPA) for the clinical trial of their internally developed product, KF-0210 tablets. The KF-0210 tablets meet the relevant requirements for drug registration and have been granted permission to p...

More >>

2022-06-21

The first patient in phase Ib clinical trial of KF-0210 tablets combined with PD-L1 antibody was enrolled

Keythera (Suzhou) Biopharmaceutical Co., Ltd. (hereinafter referred to as "Keythera") today announced that it has completed first dosing in the first patient for the phase Ib trial of KF-0210 in combination with atezolizumab supplied by Roche for patients with advanced solid tumors. The purpose of this clinical trial was to evaluate the safety, to...

More >>

2022-03-23

Keythera KF-0210/PD-L1 combination therapy: the clinical study is approved by NMPA

Keythera (Suzhou) Biopharmaceutical Co., Ltd. (hereinafter referred to as "Keythera") announced on February 18, 2022, that it has executed a clinical supply agreement with F.

More >>

2021-12-29

Great news! Keythera wins first place in the final of the 10ᵗʰ China Innovation and Entrepreneurship Competition

Technological innovation leads to great achievements! On December 28, 2021, the national final of the 10ᵗʰ China Innovation and Entrepreneurship Competition kicked off in Guangzhou High-tech Zone....

More >>

2021-10-14

Congratulations to Keythera for advancing to the final of the 10ᵗʰ China Innovation and Entrepreneurship Competition with the first-place score in the group stage.

Guided by the important thoughts of General Secretary Xi Jinping on scientific and technological innovation, the 10ᵗʰ China Innovation and Entrepreneurship Competition has received registrations from 33,289 companies in 37 regional divisions across the country since its launch in June this year, including 4,931 in the field of biopharmaceuticals....

More >>

2021-07-29

Keythera has been listed among the "2020-2021 New Economy High-Growth Enterprises TOP 50" by Financing China

On July 29, 2021, Financing China released the results of the "2020-2021 Industrial King" ranking. As the first half of the "14th Five-Year Plan" comes to an end, China's domestic gross domestic product (GDP) exceeded 53 trillion yuan in the first half of 2021...

More >>

2021-04-22

Keythera completed the first administration to a patient in China for its first-in-class investigational drug, KF-0210

KF-0210, developed independently by Keythera Biopharmaceuticals, is a small molecular drug designed to combat tumors by regulating the tumor immune microenvironment and enhancing the body's anti-tumor immune response...

More >>